Adam Huczynski (2012). "Salinomycin – a New Cancer Drug Candidate". Chemical Biology & Drug Design 79: 235–238.
Yurkovich, Marie E. et al.; Tyrakis, Petros A.; Hong, Hui; Sun, Yuhui; Samborskyy, Markiyan; Kamiya, Kohei; Leadlay, Peter F. (2011-11-11). "A Late-Stage Intermediate in Salinomycin Biosynthesis Is Revealed by Specific Mutation in the Biosynthetic Gene Cluster". ChemBioChem 13 (1): 66–71.
Gupta, P. et al.; Onder, Tamer T.; Jiang, Guozhi; Tao, Kai; Kuperwasser, Charlotte; Weinberg, Robert A.; Lander, Eric S. (2009-08-13). "Identification of selective inhibitors of cancer stem cells by high-throughput screening". Cell 138 (4): 645–59
Zhou, Shuang et al. “Salinomycin: a novel anti-cancer agent with known anti-coccidial activities” Current medicinal chemistry vol. 20,33 (2013): 4095-101.
Kim JH, Chae M, Kim WK, Kim YJ, Kang HS, Kim HS, Yoon S. Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein. Br. J. Pharmacol. 2011;162:773–784.
Eameema Muntimadugu, Rajendra Kumar, Shantikumar Saladi, Towseef Amin Rafeeqi, Wahid Khan, "CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel", Colloids and Surfaces B: Biointerfaces, Vol. 143 (2016): 532-546